150 related articles for article (PubMed ID: 37723374)
1. Factors associated with adherence to BRCA1/2 mutation testing after oncogenetic counseling in long-surviving patients with a previous diagnosis of breast or ovarian cancer.
Actis S; D'Alonzo M; Pace L; Mucciacito S; Bounous VE; Sgrò LG; Mancarella M; Ferrero A; Biglia N
J Community Genet; 2023 Dec; 14(6):649-656. PubMed ID: 37723374
[TBL] [Abstract][Full Text] [Related]
2. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
3. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
4. Participation of Korean families at high risk for hereditary breast and ovarian cancer in BRCA1/2 genetic testing.
Sun Y; Kang E; Baek H; Jung J; Hwang E; Koo J; Kim EK; Kim SW
Jpn J Clin Oncol; 2015 Jun; 45(6):527-32. PubMed ID: 25838294
[TBL] [Abstract][Full Text] [Related]
5. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
[TBL] [Abstract][Full Text] [Related]
6. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
[TBL] [Abstract][Full Text] [Related]
7. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
Armstrong K; Micco E; Carney A; Stopfer J; Putt M
JAMA; 2005 Apr; 293(14):1729-36. PubMed ID: 15827311
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
[TBL] [Abstract][Full Text] [Related]
9. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
Lerman C; Biesecker B; Benkendorf JL; Kerner J; Gomez-Caminero A; Hughes C; Reed MM
J Natl Cancer Inst; 1997 Jan; 89(2):148-57. PubMed ID: 8998184
[TBL] [Abstract][Full Text] [Related]
10. Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.
Mooney R; Espinel W; Elrick A; Kehoe K; Kohlmann W; Kaphingst KA
J Genet Couns; 2022 Apr; 31(2):470-478. PubMed ID: 34570943
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
12. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
Morgan D; Sylvester H; Lucas FL; Miesfeldt S
Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
[TBL] [Abstract][Full Text] [Related]
13. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
14. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
[TBL] [Abstract][Full Text] [Related]
15. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
16. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
[TBL] [Abstract][Full Text] [Related]
17. How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors.
Neviere Z; De La Motte Rouge T; Floquet A; Johnson A; Berthet P; Joly F
Ther Adv Med Oncol; 2020; 12():1758835919897530. PubMed ID: 32165926
[TBL] [Abstract][Full Text] [Related]
18. [Experience at Sheba Hospital in oncogenetic counseling and genetic testing of women with a high risk for breast and ovarian cancer].
Theodor L; Shiri-Sverdlov R; Yechezkel GH; Bar-Sade RB; Gak E; Friedman I; Kruglikova A; Ben-Baruch G; Risel S; Papa MZ; Goldman B; Friedman E
Harefuah; 1998 Apr; 134(8):593-9, 672. PubMed ID: 10911419
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
